OR WAIT null SECS
Feliza Mirasol is the science editor for Pharmaceutical Technology and Pharmaceutical Technology Europe.
June 21, 2022
In this episode of the Drug Solutions Podcast, Feliza Mirasol, science editor, discusses the changing parameters for oral solid dosage forms as driven by APIs and new chemical entities with Deepak Thassu, vice-president R&D and Regulatory Submission, LGM Pharma, and Marco Gil, senior vice-president of Sales & Marketing, Hovione.
May 16, 2022
The struggle to implement continuous biomanufacturing at GMP level is slowly advancing.
May 15, 2022
The need for sustainability and early considerations of a lyophilization strategy grow more pertinent on the back of growing biologics volume.
May 05, 2022
In this episode of Drug Digest, Pharmaceutical Technology editors, Felicity Thomas and Feliza Mirasol, examine the topic of emerging therapies in more detail, covering subjects such as the challenges of scale, the potential benefits of drug delivery innovation, importance of early analytical studies, the evolution of the regulatory landscape, and differences between regional regulatory requirements.
May 04, 2022
In this episode of the Drug Solutions Podcast, Feliza Mirasol, Pharmaceutical Technology’s science editor, discusses technologies enabling biologics and emerging therapies manufacturing and development with Barry Holtz, PhD, chief scientific officer of Phylloceuticals, and Professor Yaakov Nahmias, founder and chief scientific officer, Tissue Dynamics and founder and president, Future Meat Technologies.
May 03, 2022
Resolving operational bottlenecks makes mAb manufacturing more efficient.